Name | Title | Contact Details |
---|---|---|
Adrian Ionescu |
Director, Neuroscience Research & Development | Profile |
Jairo Milchteim |
Director, Finance - R&D and Medical Affairs | Profile |
Diana Smith |
Executive Director, Accounting | Profile |
Julie Cooke |
Chief People Officer | Profile |
BiPar Sciences Incorporated is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity.
Ceregene is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Seattle Biomedical Research Institute is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.